SEATTLE, May 30 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company will present updates on multiple research and development projects over the course of the five-day annual meeting of the American Society of Gene Therapy (Seattle, May 30 - June 3). Non-clinical data to be presented include:
* Analysis of Plasmid-Based Products: Development of a Novel Potency Assay, May 30, by Alain Rolland, Pharm.D., Ph.D., Vical’s Senior Vice President of Product Development. * Vaxfectin(TM)-formulated Plasmid DNA Measles Vaccine Elicits Protective Immune Response in Non-Human Primates, May 31, by Adrian Vilalta, Ph.D., Vical’s Senior Scientific Manager of Immunogen Discovery. * Vaccination with Linear Expression Cassettes Protects Mice Against Lethal Influenza A Challenge, June 2, by Adrian Vilalta, Ph.D., Vical’s Senior Scientific Manager of Immunogen Discovery.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company’s focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contacts: Investors: Media: Alan R. Engbring Susan Neath Vical Incorporated Porter Novelli Life Sciences (858) 646-1127 (619) 849-6007 Website: www.vical.com
Vical Incorporated
CONTACT: Investors, Alan R. Engbring of Vical Incorporated,+1-858-646-1127; Media, Susan Neath of Porter Novelli Life Sciences,+1-619-849-6007
Web site: http://www.vical.com//
